Psilocybin Depression Study

psilocybin depression study

Psiloscience.ca is a team of ordinary people having an extraordinary vision of helping those who can’t do it alone. Since 2017, they have devoted their time and effort in perfecting their products that can provide relief to people with mental conditions.

How can psilocybin help treat depression?

Various researches and clinical trials from reputable universities and laboratories point to the fact that psilocybin providing relief to patients suffering from depression. This psilocybin depression study found out that psilocybin can significantly rewire the brain’s key circuits that are responsible for depression. They also found out that there might be a direct link between an increase in post-treatment and peak experience in the brain’s various regions. This peak experience can lead to improving connectivity after the experience. The latter, on the other hand, can lead to improved therapeutic results.

In some researches, patients were shown faces holding different kinds of emotions -- happy, neutral, fearful, while they faced a scanner. Their brain analyses were focused and centered on the amygdala, the brain region responsible for stress and fear processing. Activities in the amygdala were stronger when the research patients were shown fearful faces after they underwent psilocybin sessions. Before they were subjected to psilocybin sessions, the brain activities were not that active.

This only means that psilocybin enhances the brain’s response to various negative stimuli. This is a surprising result for most researchers. The more common preconception is that an effective anti-depressant should dampen or reduce brain activity. The researchers also found that the great thing about this improved response is directly linked to greater improvement. This suggests that therapies using psilocybin treat depression thru increasing the person’s emotional responsiveness.

What are the other relevant observations of the researchers of psilocybin depression study?

Apart from the aforementioned, the researchers also found out that most of the patients experienced a greater will to fully accept all these negative emotions. These answers and feedback from the research patients clearly sealed the effectiveness of the psilocybin depression study.

Most of these research patients also said that their past depression treatment programs worked to make them avoid negative emotions. In contrast, their experience with psilocybin treatment made them confront these stream of emotions. They even described the experience as a challenging comeback to traumas rooted in the past that resulted in an emotional resolution and breakthrough. Though this process was far from being pleasant or easy, they felt that the entire process was pivotal to reaching a positive therapeutic conversion.

Psiloscience.ca has been working their best to provide the people in the community, especially those suffering from various mental conditions, get access to these 100% natural, organic, and non-GMO remedy. For them, mental health can be improved without the use of synthetic and lab-produced medicines that only produce inconceivable side effects.

Mother nature has so much to offer and one of these is micro dosing magic mushroom. They also believe that social anxiety treatments, coupled with psilocybin treatment can greatly improve an individual’s mental health along with his quality of living.

Related Post

Psilocybin Treatment Resistant Depression

Psiloscience.ca has been dedicating their time and effort in perfecting a 100% natural and non-GMO treatment for people suffering from various kinds of mental illnesses. Their breakthrough product is the use of psilocybin, the potent ingredient of magic mushrooms. Clinical tests and various studies have been conducted and all these points to the fact that psilocybin can significantly help treat depression.

Is psilocybin treatment scientifically approved?

The answer to this question is plain and downright yes. As a matter of fact, researchers all over the world are currently fast-tracking in developing depression treatment programs using psilocybin.

Last year, the FDA already issued a designation to psilocybin treatment resistant depression drug done by COMPASS Pathways. This only suggests that accelerated studies and approval procedures related to drugs bearing reliable and persuasive preliminary evidence are taking place. The studies in the past already showed that psilocybin treatments can afford an immediate and prolonged reduction of depression even after a single treatment.

The effects were described as psilocybin shaking up the brain akin to a snow globe. Also, some research patients explained that they felt that their brains underwent a reboot, gathering new connections while deactivating those old ones which might cause the depression.

Since 1950, psilocybin therapy has already been controversial. This treatment method involves psychoactive medicine, psychological support, and the use of psychedelic mushrooms. Dr. Charles Raison, MD, School of Human Ecology professor at the Wisconsin-Madison University said that therapies based on mushrooms were originally observed and used among patients with cancer or those suffering from severe alcoholism. It was in the early part of 2000 that investigators who were privately funded noticed the positive effects of these substances on the patient’s mood.

What are the effects of psilocybin on those who took it?

Different clinical trials and research conducted by laboratories, privately-funded institutions, and universities revealed the positive effects of psilocybin treatment resistant depression on patients suffering from various mental conditions. One of the most notable effects is that it rewired the individuals’ brains and fine-tuning the circuits that caused negative emotions. In the process of finding this out, the researchers also discovered the relationship between the brain’s peak experience and the post-treatment frequency. The former was found to have resulted in improved connectivity after the therapy. The frequency of the post-treatment therapy, on one hand, led to better treatment results.

Part of the research results to bolster the efficacy of psilocybin in treating depression is another study wherein various patient respondents were shown faces carrying different kinds of human emotions. There were faces showing fear, neutral emotions, and happiness.

While they were shown these emotions, their brain activities, especially the activities in their amygdala, were analyzed. It was found out that those patients showed improved brain activities when shown a negative emotion after they underwent the therapy. Though this result is quite the opposite of the preconceived notions, the researchers were able to find a great link and explanation why.

According to them, a stronger and better response means a great improvement in emotion processing. While the patient’s brain activities grow stronger, they also improved their emotional responsiveness. This responsiveness allows the acceptance and resolution of these negative emotions causing depression.

Psilocybin Research Depression

Psiloscience.ca is a team of ordinary individuals who aimed to achieve significant results in providing natural remedies to people suffering from a mental condition. They started their campaign in 2017 and since then, they have been providing CBD Oil, Psilocybin Edible, Psilocybin Microdose, THC Vape pen, and other psilocybin-based products.

What are Psiloscience.ca’s bases in advocating for psilocybin in treating depression?

Classified as a classic hallucinogen, psilocybin is an example of a chemical that is derived from 100 and more mushroom species worldwide. Based on studies, psilocybin has a great affinity for various serotonin receptors like 5-HT2C, 5-HT2A, 5-HT1A, These receptors are found in various areas in the brain like the thalamus and the cerebral cortex. In 1992, legislation was introduced that spurred the more in-depth study on the implications and/or repercussions of psilocybin when used as a treatment in various stages of certain diseases. Among the mental disease symptoms and states that were studied under Psilocybin Research Depression include the following:

  • Alcohol use disorder
  • Anxiety disorders
  • Depressed mood
  • OCD or Obsessive-compulsive disorder
  • Tobacco abuse

One of the studies that supported Psiloscience.ca’s advocacy is that of Hendricks, Griffiths, and Johnson. They studied the relationship between psychological distress and lifetime use of psilocybin. As part of their study, they also recounted and considered their respondent’s suicide attempts, suicide plans, and instances wherein they’ve thought of committing suicide and how these are associated with psilocybin usage.

This group of researchers utilized the data collected by the National Survey on Drug Use and Health from 2008 to 2012. The said survey grouped their respondents into 4 – psilocybin users, users of psilocybin and other kinds of psychedelics, users of other psychedelics, and none-users. The results showed that suicidal thoughts and planning were significantly lower in the group that used psilocybin only compared to those who used psilocybin along with other psychedelics.

Aside from that, the group that only used psilocybin suffered less psychological distress compared to the other groups. The results of the study conducted by Hendricks, et.al, supports the hypothesis that psilocybin significantly reduces suicidal thoughts and improves the patient’s mood.

What are the follow-up studies that were conducted to support Hendricks group’s findings?

Aside from the Psilocybin Research Depression study conducted by Hendricks and his team, in 2006 and in 2008, Griffiths, Richard, and  McCann U published their studies which examined the psychological impact of psilocybin among healthy respondents. In their study, hallucinogen-naïve participants were administered methylphenidate or oral psilocybin within 2 to 3 repetitions. These participants were also informed that they will be given average to high psilocybin doses in 1 to 2 sessions.

After 2 months and 14 months, a follow-up was made on the patients and the results were quite telling. The patients who were only administered with psilocybin reported a significant increase in positive behavior, social effects, mood, and attitudes compared to those who were given methylphenidate. The researchers felt that their study’s breakthrough finding is that a huge chunk of their respondent population rated their experience being administered with psilocybin as their most meaningful life experience.

We welcome your comments!